Use of evidence-based pharmacotherapy after myocardial infarction in Estonia.

Publisher: BioMed Central Country of Publication: England NLM ID: 100968562 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2458 (Electronic) Linking ISSN: 14712458 NLM ISO Abbreviation: BMC Public Health Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Guideline Adherence*; Adrenergic beta-Antagonists/*therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/*therapeutic use ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use ; Myocardial Infarction/*drug therapy; Adult ; Aged ; Aged, 80 and over ; Drug Utilization ; Estonia ; Evidence-Based Medicine ; Female ; Humans ; Male ; Middle Aged

Background: Mortality from cardiovascular disease in Estonia is among the highest in Europe. The reasons for this have not been clearly explained. Also, there are no studies available examining outpatient drug utilization patterns in patients who suffered from acute myocardial infarction (AMI) in Estonia. The objective of the present study was to examine drug utilization in different age and gender groups following AMI in Estonia.
Methods: Patients admitted to hospital with AMI (ICD code I21-I22) during the period of 01.01.2004-31.12.2005 and who survived more than 30 days were followed 365 days from the index episode. Data about reimbursed prescriptions of beta-blockers (BBs), angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (ACE/ARBs) and statins for these patients was obtained from the database of the Estonian Health Insurance Fund. Data were mainly analysed using frequency tables and, where appropriate, the Pearson's chi2 test, the Mann-Whitney U-test and the t-test were used. A logistic regression method was used to investigate the relationship between drug allocation and age and gender. We presented drug utilization data as defined daily dosages (DDD) per life day in four age groups and described proportions of different combinations used in men and women.
Results: Four thousand nine hundred patients were hospitalized due to AMI and 3854 of them (78.7%) were treated by BBs, ACE/ARBs and/or statins. Of the 4025 inpatients who survived more than 30 days, 3799 (94.4%) were treated at least by the one of drug groups studied. Median daily dosages differed significantly between men and women in the age group 60-79 years for BBs and ACE/ARBs, respectively. Various combinations of the drugs studied were not allocated in equal proportions for men and women, although the same combinations were the most frequently used for both genders. The logistic regression analysis adjusted to gender and age revealed that some combinations of drugs were not allocated similarly in different age and gender groups.
Conclusions: Most of the patients were prescribed at least one of commonly recommended drugs. Only 40% of them were treated by combinations of beta-blockers, ACE inhibitors/angiotensin II receptor blockers and statins, which is inconsistent with guideline recommendations in Estonia. Standards of training and quality programs in Estonia should be reviewed and updated aiming to improve an adherence to guidelines of management of acute myocardial infarction in all age and gender groups.

Eur Heart J. 2006 May;27(10):1153-8. (PMID: 16399775)
J Manag Care Pharm. 2008 Apr;14(3):271-80. (PMID: 18439049)
Am Heart J. 2007 Dec;154(6):1108-15. (PMID: 18035083)
Lancet. 2005 Jan 1-7;365(9453):82-93. (PMID: 15639683)
Am Heart J. 2006 Sep;152(3):454.e1-8. (PMID: 16923412)
Eur Heart J. 2006 Apr;27(7):789-95. (PMID: 16464911)
Eur Heart J. 2003 Jan;24(1):28-66. (PMID: 12559937)
JAMA. 2007 Jan 10;297(2):177-86. (PMID: 17213401)
Am Heart J. 2003 Mar;145(3):438-44. (PMID: 12660666)
Eur Heart J. 2006 Oct;27(19):2285-93. (PMID: 16908490)
Am J Med. 2004 Jul 15;117(2):73-81. (PMID: 15234641)
Eur Heart J. 2008 Dec;29(23):2909-45. (PMID: 19004841)
Am J Med. 2004 Jul 15;117(2):130-2. (PMID: 15234651)
BMJ. 2006 Nov 25;333(7578):1091. (PMID: 17032691)
Eur Heart J. 2005 May;26(9):873-80. (PMID: 15681575)
Scand J Public Health. 2006;34(3):327-31. (PMID: 16754592)
Eur Heart J. 2007 Jul;28(13):1598-660. (PMID: 17569677)
J Am Coll Cardiol. 2007 Jul 3;50(1):1-13. (PMID: 17601538)
Acta Cardiol. 2004 Jun;59(3):275-81. (PMID: 15255459)
Eur Heart J. 2002 Dec;23(23):1809-40. (PMID: 12503543)

0 (Adrenergic beta-Antagonists)
0 (Angiotensin-Converting Enzyme Inhibitors)
0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)

Date Created: 20100624 Date Completed: 20130214 Latest Revision: 20240324

20240324

PMC2911401

10.1186/1471-2458-10-358

20569449